Alivus Life Sciences Ltd (NSE: ALIVUS) shares increased by 1.36% to ₹873.00 on the National Stock Exchange on Thursday. The stock reached an intraday high of ₹889.95 and a low of ₹819.00 following the announcement of its financial results for the third quarter of fiscal year 2026. The company’s market capitalization stood at ₹107.10 billion as of Thursday’s close, which is approximately $1.17 billion.
Latest Quarterly Results
Alivus Life Sciences reported a consolidated revenue from operations of ₹6.73 billion for the quarter ended December 31, 2025. This represents a 4.8% increase compared to ₹6.42 billion in the same period of the previous fiscal year. Consolidated net profit reached ₹1.50 billion, a year-on-year growth of 9.71% from ₹1.37 billion.
Operating profit, measured as EBITDA, rose to ₹2.31 billion, with margins expanding to a record 34.37% from 31.3% in the year-ago quarter.
Segment performance highlights:
- Generic API: Revenue from the active pharmaceutical ingredient (API) segment contributed 89% of total income.
- CDMO: The contract development and manufacturing organization (CDMO) segment recorded volume growth, although the company noted continued focus on high-potency molecules.
Financial Trends
Full-Year Results Context
For the full fiscal year ended March 31, 2025, the company (formerly Glenmark Life Sciences) reported a total revenue of ₹23.87 billion. Annual profit stood at ₹4.86 billion. Directional trends over the last two fiscal cycles show a stable expansion in revenue and a consistent maintenance of debt-free status.
Business & Operations Update
The company transitioned to its new corporate identity, Alivus Life Sciences, following the acquisition of a majority stake by Nirma Limited. During the quarter, the company reported the addition of new technology platforms, including flow chemistry, and the advancement of its high-potent API pipeline, which currently includes 21 molecules. Capacity expansion at the Solapur greenfield site and brownfield additions at Dahej and Ankleshwar remain in progress to support long-term volume requirements.
M&A or Strategic Moves
Nirma Limited remains the majority promoter following its 75% stake acquisition from Glenmark Pharmaceuticals. No new institutional-level mergers or acquisitions were announced during the third quarter disclosure.
Equity Analyst Commentary
Institutional research from Kotak Institutional Equities and Marketsmojo noted the company’s margin expansion as a result of a favorable product mix and lower raw material input costs. Analysts indicated that the CDMO segment’s recovery and the scaling of the oncology and iron complex portfolios are key monitoring factors for the next fiscal year.
Guidance & Outlook
Alivus Life Sciences has indicated a volume growth target in the mid-teens for the remainder of the fiscal year. The company identified the commercialization of new molecules and the stabilization of logistics costs as primary factors to watch for in the upcoming quarter.
Performance Summary
Alivus Life Sciences stock closed 1.36% higher at ₹873.00. The company achieved a record quarterly revenue of ₹6.73 billion and a net profit of ₹1.50 billion. Record EBITDA margins of 34.37% reflected operational efficiency gains within the core Generic API segment.